[HTML][HTML] 21-gene assay to inform chemotherapy benefit in node-positive breast cancer
…, LJ Goldstein, SKL Chia, S Dhesy-Thind… - … England Journal of …, 2021 - Mass Medical Soc
Background The recurrence score based on the 21-gene breast-cancer assay has been
clinically useful in predicting a chemotherapy benefit in hormone-receptor–positive, human …
clinically useful in predicting a chemotherapy benefit in hormone-receptor–positive, human …
[PDF][PDF] PANCREOX: a randomized phase III study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have …
S Gill, YJ Ko, C Cripps, A Beaudoin, S Dhesy-Thind… - J Clin …, 2016 - researchgate.net
Purpose The standard of care for second-line therapy in patients with advanced pancreatic
cancer after gemcitabine-based therapy is not clearly defined. The CONKO-003 phase III …
cancer after gemcitabine-based therapy is not clearly defined. The CONKO-003 phase III …
[PDF][PDF] Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical …
S Dhesy-Thind, GG Fletcher, PS Blanchette… - J Clin …, 2017 - medicalrp.com.mx
Purpose: To make recommendations regarding the use of bisphosphonates and other bone-modifying
agents as adjuvant therapy for patients with breast cancer. Methods: Cancer Care …
agents as adjuvant therapy for patients with breast cancer. Methods: Cancer Care …
Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET)+/-chemotherapy (CT) in patients (pts) with 1-3 …
…, S Chia, S Dhesy-Thind, P Rastogi, E Alba, S Delaloge… - Cancer Research, 2021 - AACR
… At this time, there is no differential effect with CT in regard to other stratification factors.
Conclusions: There is a significant differential treatment effect of CT benefit based on RS for …
Conclusions: There is a significant differential treatment effect of CT benefit based on RS for …
[HTML][HTML] Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update)
E Grunfeld, S Dhesy-Thind, M Levine - Cmaj, 2005 - Can Med Assoc
… Thus, although there is some evidence of a positive relation between weight management
… Contributors: Eva Grunfeld, Sukhbinder Dhesy-Thind and Mark Levine contributed equally to …
… Contributors: Eva Grunfeld, Sukhbinder Dhesy-Thind and Mark Levine contributed equally to …
[PDF][PDF] Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology–Cancer Care Ontario focused guideline update
…, MJ Clemons, SK Dhesy-Thind… - Journal of Clinical …, 2017 - cancercareontario.ca
Purpose To update, in collaboration with Cancer Care Ontario (CCO), key recommendations
of the American Society of Clinical Oncology (ASCO) guideline on the role of bone-…
of the American Society of Clinical Oncology (ASCO) guideline on the role of bone-…
Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update
…, MJ Clemons, S Dhesy-Thind… - Journal of Clinical …, 2022 - ingentaconnect.com
PURPOSE To update recommendations of the American Society of Clinical Oncology (ASCO)-Ontario
Health (Cancer Care Ontario [CCO]) adjuvant bone-modifying agents in breast …
Health (Cancer Care Ontario [CCO]) adjuvant bone-modifying agents in breast …
Clinical practice guidelines in breast cancer
NK Tyagi, S Dhesy-Thind - Current Oncology, 2018 - mdpi.com
Background: A number of clinical practice guidelines (CPGS) concerning breast cancer (BCA)
screening and management are available. Here, we review the strengths and …
screening and management are available. Here, we review the strengths and …
A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group …
Background Pelareorep, a serotype 3 reovirus, has demonstrated preclinical and early clinical
activity in breast cancer and synergistic cytotoxic activity with microtubule targeting agents…
activity in breast cancer and synergistic cytotoxic activity with microtubule targeting agents…
Safety of continuing trastuzumab despite mild cardiotoxicity: a phase I trial
…, PM Ellis, SD Mukherjee, S Dhesy-Thind - Cardio Oncology, 2019 - jacc.org
… needed to better understand whether the strategy of continuing trastuzumab despite mild
cardiotoxicity is advisable. We believe that such a trial is particularly important because LVEF …
cardiotoxicity is advisable. We believe that such a trial is particularly important because LVEF …